Dr. Sausville is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
22 S Greene St
Baltimore, MD 21201Phone+1 410-328-7394Fax+1 410-328-6896
Education & Training
National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 1982 - 1985
Brigham and Women's HospitalResidency, Internal Medicine, 1979 - 1982
Albert Einstein College of MedicineClass of 1979
Certifications & Licensure
MD State Medical License 1982 - 2023
DC State Medical License 1988 - 2016
VA State Medical License 1982 - 2004- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
- Whos Who in Medicine and Healthcare Marquis Whos Who
Clinical Trials
- Monoclonal Antibody Therapy in Treating Patients With Recurrent or Refractory Lymphoma Start of enrollment: 2000 Nov 01
- Flavopiridol in Treating Patients With Refractory Cancer Start of enrollment: 1997 Aug 01
- Perifosine in Treating Patients With Refractory Solid Tumors or Hematologic Cancer Start of enrollment: 1999 Aug 01
- Join now to see all
Publications & Presentations
PubMed
- 136 citationsPhase I dose-escalation study of AZD7762, a checkpoint kinase inhibitor, in combination with gemcitabine in US patients with advanced solid tumors.Edward A. Sausville, Patricia LoRusso, Michael A. Carducci, Judith Carter, Mary F. Quinn
Cancer Chemotherapy and Pharmacology. 2014-01-22 - 34 citationsFirst-in-human phase 1 study of filanesib (ARRY-520), a kinesin spindle protein inhibitor, in patients with advanced solid tumorsPatricia LoRusso, Priscila H. Goncalves, Lindsay Casetta, Judith A. Carter, Kevin Litwiler
Investigational New Drugs. 2015-02-17 - 750 citationsCharacterization of the p53 Tumor Suppressor Pathway in Cell Lines of the National Cancer Institute Anticancer Drug Screen and Correlations with the Growth-Inhibitory ...Patrick M. O'Connor, Joany Jackman, Insoo Bae, Timothy G. Myers, Saijun Fan
Cancer Research. 1997-10-01
Grant Support
- Umgcc PAUL Calabresi Clinical Oncology Training ProgramNational Cancer Institute2008–2011
- Clinical Research Shared ServiceNational Cancer Institute2008–2010
- Clinical Trial: Treatment Of Melanoma With Wild-Type P53 And A 100b Using PentaNational Center For Research Resources2009
- Treatment Of Melanoma With Wild-Type P53 And Detectable S100B Using Pentamidine:National Cancer Institute2008–2009
- Clinical Trial: Phase I Study Of IV 17-AAG And Oral BAY 43-9006 In Patients WithNational Center For Research Resources2008
- 0629gcc: A Phase I, Open-Label, Multi-Center, Dose-Escalation Study To Assess SLNational Center For Research Resources2007
- 0458gcc: A Phase I Dose Escalation Study Of Intravenous 17-AAGNational Center For Research Resources2007
- Phase 1 Of Sorafenib PLUS 17AAG In Solid Tumor PatientsNational Center For Research Resources2006
- Immunotoxin Protocols Under The Medicine Branch: TargeteDivision Of Clinical Sciences - Nci2001
- Protein Kinase Antagonists: Preclinical And ClinicalDivision Of Clinical Sciences - Nci1999–2001
- Immunotoxin Protocols Under The Medicine Branch: Targeted Therapy Of Lymphoid NEDivision Of Clinical Sciences - Nci2000
- Immunotoxin Protocols Under The Medicine Branch: Targeted Therapy Of Lymphoid NEODivision Of Clinical Sciences - Nci1999
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
